Recombinant Human CD300d Fc Chimera Protein, CF

Recombinant Human CD300d Fc Chimera (Catalog # 10273-CD) inhibits anti-CD3 antibody induced IL-2 secretion by human T cells. The ED50 for this effect is 1‑6 μg/mL.

2 μg/lane of Recombinant Human CD300d Fc Chimera (Catalog # 10273-CD) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 50-70 kDa and 100-140 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD300d Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1-6 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human CD300d protein
  

  Human CD300d (Ala19-His165) Accession # Q6UXZ3	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6UXZ3
• N-terminal Sequence: Ala19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 43 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 50-70 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD300d Fc Chimera Protein, CF

• CD300 molecule-like family member d
• CD300d
• CD300LD
• CLM-5
• CMRF35-A4
• immune receptor CD300d
• MAIR-IV

Background

CD300d (also known as CD300LD or CMRF35A4) is a member of the CD300 family of transmembrane glycoproteins belonging to the immunoregulatory signaling (IRS) family. CD300d, like most CD300 family members, is found exclusively on myeloid cells, including monocyte and granulocytes (1). CD300 members contain a V-type immunoglobulin-like domain with an additional pair of cysteine residues in the extracellular domain (ECD), a transmembrane region, and a short cytoplasmic tail (2, 3). The mature ECD of human CD300d is 146 amino acids (aa) and shares a 48% and 45% identity with mouse and rat CD300d, respectively. CD300d recruits ITAM-bearing Adaptor FceRg. CD300d interacts with all CD300 family members with exception of CD300c, and plays a role in the regulation and/or formation of CD300 complexes on the cell surface and consequently modulate the state of activation of myeloid cells. CD300 family members modulate a broad and diverse array of immune cell processes via their paired activating and inhibitory receptor functions (2, 3). Mouse CD300d, along with CD300lf, has been identified as a receptor for permissive murine noroviral infection (MNoV) (4). Further, expression of murine CD300LF on human and other mammalian cell lines confers cross‑species permissively (5). Additional research into CD300 family member function during viral infections could help develop novel anti-viral therapies (6). Our in‑house data indicate that CD300D inhibits T cell activation, including anti-CD3 induced IL-2 and IFN-gamma secretion.

1. Comas-Casellas, E. et al. 2011. J. Biol. Chem. 287:9682.
2. Clark, G.J. et al. (2009) Trends in Immunology 30:209.
3. Borrego F. (2013) Blood 121:1951.
4. Haga, K. et al. 2016. PNAS. 113:E6248.
5. Orchard, R. et al. 2016. Science. 353:933.
6. Graziano, V et al. 2019. Viruses. 11:pii.

Bioinformatics

• Uniprot:
  • Q6UXZ3()